Home Tags Diabetes: Type II

Tag: Diabetes: Type II

Bariatric surgery is tied to lower overall incidence of microvascular disease in patients with type 2 diabetes mellitus

Bariatric Surgery Lowers Microvascular Disease Risk

Findings based on large study of patients with type 2 diabetes
Greater adherence to an overall healthy lifestyle is associated with a substantially lower risk of cardiovascular disease incidence and mortality among adults with type 2 diabetes

Healthy Lifestyle With Diabetes Cuts Cardiovascular Risk

Benefit seen for adoption of healthy lifestyle even after T2DM diagnosis made
One-quarter of older adults with type 2 diabetes in the United States are tightly controlled using glucose-lowering medications with a high risk of hypoglycemia

One-Quarter of Older U.S. Adults May Be Overtreated for Diabetes

These patients are tightly controlled with glucose-lowering medications with high risk of hypoglycemia
Nut intake reduces hemoglobin A1c among individuals with type 2 diabetes

Nut Intake Reduces HbA1c Among Adults With T2DM

Full-nut dose lowered HbA1c, estimated cholesterol levels in LDL particles with diameter <255 ångströms
Sulfonylureas as second-line drugs for type 2 diabetes are associated with an increased risk of cardiovascular and hypoglycemic events compared with remaining on metformin monotherapy or adding to metformin therapy

Sulfonylureas As 2nd-Line T2DM Therapy Tied to Higher Event Risk

Associated with increased risk of myocardial infarction, all-cause mortality, severe hypoglycemia
For patients with type 2 diabetes

Intermittent Energy Restriction Effectively Cuts HbA1c in T2DM

Intermittent energy restriction equivalent to continuous energy restriction for reducing HbA1c
Empagliflozin does not increase the risk of bone fracture in patients with type 2 diabetes

Empagliflozin Doesn’t Up Risk of Bone Fractures

Per pooled data from placebo-controlled trials and data from a head-to-head study with glimepiride
For patients with type 2 diabetes

Characteristics of Severe Hypoglycemia Identified in T2DM

Increased odds of severe hypoglycemia with history of non-severe hypoglycemia, HbA1c <6 percent
Basal insulin analogues for type 2 diabetes mellitus do not substantially differ in their glucose-lowering effect

Basal Insulin Analogues Similar for Glucose Lowering

Slight differences in risk for nocturnal hypoglycemia or weight gain exist
Many patients with type 2 diabetes who have a hemoglobin A1c level expected to trigger treatment intensification often have treatment inappropriately delayed

Evidence of Clinical Inertia in Management of T2DM

No treatment intensification for many patients with HbA1c threshold expected to trigger intensification